Chen Jia-Hong, Chen Wei-Liang, Chan James Yi-Hsin, Chen Yuan-Wu, Peng Yi-Jen, Cheng Ming-Fang, Lin Chun-Shu
Division of Medical Oncology and Haematology, Tri-Service General Hospital, National Defense Medical Centre, Taipei 11490, Taiwan, R.O.C.
Division of Family Medicine, Tri-Service General Hospital, National Defense Medical Centre, Taipei 11490, Taiwan, R.O.C.
Oncol Lett. 2017 Nov;14(5):6103-6108. doi: 10.3892/ol.2017.6966. Epub 2017 Sep 15.
The aim of the present study was to investigate the association between cluster of differentiation (CD) 164 expression with clinicopathological parameters and prognosis among patients with oral cavity squamous cell carcinoma (OSCC). The present study retrospectively reviewed 70 patients with OSCC who underwent curative primary surgery. A number of patients subsequently received postoperative chemoradiotherapy although the specimens were not exposed to radiation or chemotherapy prior to anti-CD164 antibody immunohistochemical staining. CD164 overexpression was arbitrarily defined as exhibiting an H-score of ≥120. Univariate and multivariate analyses were performed for sex, age, American Joint Committee on Cancer stage, tumour location, histological grade, surgical margin and H-score. The 5-year overall survival rate was 54.4% and the median follow-up time was 46 months for surviving patients. Univariate analyses revealed that a low overall survival rate was associated with advanced-stage disease (P<0.001), buccogingival tumour location (P=0.038) and a CD164 H-score of <120 (P=0.016). Multivariate Cox's regression analyses revealed that poor overall survival rate was associated with advanced-stage disease (P=0.001) and a CD164 H-score of <120 (P=0.04). CD164 overexpression in OSCC was associated with favourable survival rate. Thus, CD164 expression may be a clinically useful predictor of prognosis in patients with OSCC.
本研究的目的是调查口腔鳞状细胞癌（OSCC）患者中分化簇（CD）164表达与临床病理参数及预后之间的关联。本研究回顾性分析了70例行根治性原发手术的OSCC患者。尽管在抗CD164抗体免疫组化染色前标本未接受放疗或化疗，但部分患者随后接受了术后放化疗。CD164过表达被任意定义为H评分≥120。对性别、年龄、美国癌症联合委员会分期、肿瘤位置、组织学分级、手术切缘和H评分进行单因素和多因素分析。5年总生存率为54.4%，存活患者的中位随访时间为46个月。单因素分析显示，总生存率低与晚期疾病（P<0.001）、颊龈部肿瘤位置（P=0.038）和CD164 H评分<120（P=0.016）相关。多因素Cox回归分析显示，总生存率低与晚期疾病（P=0.001）和CD164 H评分<120（P=0.04）相关。OSCC中CD164过表达与良好的生存率相关。因此，CD164表达可能是OSCC患者预后的一个临床有用的预测指标。
